A Series of N-of-1 Trials for Traditional Chinese Medicine Using a Bayesian Method: Study Rationale and Protocol

Lizhi Lu, Jiaqi An, Huijia Chen, Peilan Yang, Minhua Xu, Yingen Wu, Zhenwei Wang, Lihua Shen, Xinlin Chen, Haiyin Huang, Lizhi Lu, Jiaqi An, Huijia Chen, Peilan Yang, Minhua Xu, Yingen Wu, Zhenwei Wang, Lihua Shen, Xinlin Chen, Haiyin Huang

Abstract

Background. Our previous studies showed that N-of-1 trials could reflect the individualized characteristics of traditional Chinese medicine (TCM) syndrome differentiation with good feasibility, but the sensitivity was low. Therefore, this study will use hierarchical Bayesian statistical method to improve the sensitivity and applicability of N-of-1 trials of TCM. Methods/Design. This is a randomized, double-blind, placebo-controlled, three-pair crossover trial for a single subject, including 4-8 weeks of run-in period and 24 weeks of formal trial. In this study, we will recruit a total of 30 participants who are in the stable stage of bronchiectasis. The trial will be divided into three pairs (cycles), and one cycle contains two observation periods. The medications will be taken for three weeks and stopped for one week in the last week of each observation period. The order of syndrome differentiation decoction and placebo will be randomly determined. Patient self-reported symptom score (on a 7-point Likert scale) is the primary outcome. Discussion. Some confounding variables (such as TCM syndrome type and potential carryover effect of TCM) will be introduced into hierarchical Bayesian statistical method to improve the sensitivity and applicability of N-of-1 trials of TCM, and the use of prior available information (e.g., "borrowing from strength" of previous trial results) within the analysis may improve the sensitivity of the results of a series of N-of-1 trials, from both the individual and population level to study the efficacy of TCM syndrome differentiation. It is the exploration of improving the objective evaluation method of the clinical efficacy of TCM and may provide reference value for clinical trials of TCM in other chronic diseases. This trial is registered with ClinicalTrials.gov (ID: NCT04601792).

Conflict of interest statement

All authors declare no conflicts of interest.

Copyright © 2021 Lizhi Lu et al.

Figures

Figure 1
Figure 1
The flowchart of the N-of-1 trials in the treatment of stable bronchiectasis by traditional Chinese medicine based on syndrome differentiation.

References

    1. Huang H. Y., Yang P. L., Zhang Y. Q., Xue J. J., Xu M. H. Potential value and feasibility of N-of-1 randomized controlled trials in research of traditional Chinese medicine. Shanghai Journal of Traditional Chinese Medicine. 2012;46(8):3–8.
    1. Liu J. P., Zhang M., Yang M., et al. The application of the design of N-of-1 randomized controlled trials in research of traditional Chinese medicine. Chinese Journal of Information on Traditional Chinese Medicine. 2002;9(6):66–68.
    1. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford, UK: Oxford Centre for Evidence-Based Medicine; 2011.
    1. Shamseer L., Sampson M., Bukutu C., et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration. BMJ. 2015;350:p. h1793. doi: 10.1136/bmj.h1793.
    1. The Writing Group of Consensus of the Experts on the Diagnosis and Treatment of Bronchiectasis. Consensus of the experts on the diagnosis and treatment of bronchiectasis. Zhong Hua Jie He He Hu Xi Za Zhi. 2013;36(8):563–566.
    1. Guan W. J., Gao Y. H., Yuan J. J., Chen R. C., Zhong N. S. Additional important research priorities for bronchiectasis in China. European Respiratory Journal. 2017;49(1):p. 1601747. doi: 10.1183/13993003.01747-2016.
    1. Lin J. L., Xu J. F., Qu J. M. Bronchiectasis in China. Annals of the American Thoracic Society. 2016;13(5):609–616. doi: 10.1513/annalsats.201511-740ps.
    1. Chandrasekaran R., Mac Aogáin M., Chalmers J. D., Elborn S. J., Chotirmall S. H. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulmonary Medicine. 2018;18(1):p. 83. doi: 10.1186/s12890-018-0638-0.
    1. Huang H. Y., Yang P. L., Tang J. Long term effect of the treatment method of strengthening vital Qi, transforming Phlegm and clearing heat for 46 cases of bronchiectasis. Journal of Traditional Chinese Medicine. 2012;53(10):848–852.
    1. Huang H. Y., Yang P. L., Wang J., et al. Investigation into the individualized treatment of traditional Chinese medicine through a series of N-of-1 trials. Evidence-based Complementary and Alternative Medicine. 2018;2018:11. doi: 10.1155/2018/5813767.5813767
    1. Huang Y. H., Liu Q., Liu Y., et al. An N-of-1 trial service in clinical practice: testing the effectiveness of Liuwei Dihuang decoction for kidney-yin deficiency syndrome. Evidence-Based Complementary and Alternative Medicine. 2013;2013:7. doi: 10.1155/2013/827915.827915
    1. Chen X. L., Liu F. B., Zhao F., et al. Exploration of design protocols and models suitable for N-of-1 trials of traditional Chinese medicine. Journal of Guangzhou University of Traditional Chinese Medicine. 2018;35(1):172–175.
    1. Chen X. L., Chen P. A comparison of four methods for the analysis of N-of-1 trials. PLoS One. 2014;9(2) doi: 10.1371/journal.pone.0087752.e87752
    1. Senior H. E. J., Mitchell G. K., Nikles J., et al. Using aggregated single patient (N-of-1) trials to determine the effectiveness of psychostimulants to reduce fatigue in advanced cancer patients: a rationale and protocol. BMC Palliative Care. 2013;12(1):p. 17. doi: 10.1186/1472-684x-12-17.
    1. Zhai J. B., Li J., Shang H., Wang H. Brief introduction of Bayesian N-of-1 trials. Chinese Journal of EvidenceBased Medicine. 2017;17(7):848–851. doi: 10.7507/1672-2531.201701079.
    1. Duan N., Kravitz R. L., Schmid C. H. Single-patient (N-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. Journal of Clinical Epidemiology. 2013;66(8):S21–S28. doi: 10.1016/j.jclinepi.2013.04.006.
    1. Higgins J. P. T., Whitehead A. Borrowing strength from external trials in a meta-analysis. Statistics in Medicine. 1996;15(24):2733–2749. doi: 10.1002/(sici)1097-0258(19961230)15:24<2733::aid-sim562>;2-0.
    1. Huang H. Y., Yang P. L., Xue J. J., et al. Evaluating the individualized treatment of traditional Chinese medicine: a pilot study of N-of-1 trials. Evidence-based Complementary and Alternative Medicine. 2014;2014:p. 10. doi: 10.1155/2014/148730.148730
    1. Guyatt G. H. Users’ guides to the medical literature: a manual for evidence-based clinical practice. Annals of Emergency Medicine. 2002;40(1):p. 132.
    1. Polverino E., Goeminne P. C., McDonnell M. J., et al. European respiratory society guidelines for the management of adult bronchiectasis. European Respiratory Journal. 2017;50(3) doi: 10.1183/13993003.00629-2017.1700629
    1. The State Administration of Traditional Chinese Medicine. Criteria of Diagnosis and Therapeutic Effect of TCM Diseases. Nanjing, China: Nanjing University Press; 1994.
    1. Zhang H. Y., Li X., Ni W., Chen F., Shao C. Chinese medical syndrome differentiation laws of bronchiectasis. Shanghai Journal of Traditional Chinese Medicine. 2005;39(1):16–18.
    1. Pasteur M. C., Bilton D., Hill A. T. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65(1):i1–i58. doi: 10.1136/thx.2010.136119.
    1. Chen M., Huang N. J., Wang Y. S. Clinical observation on Xiehuo Zhitong decoction in treatment of migraine with liver-fire ascending syndrome. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease. 2015;13(12):1375–1377.
    1. Guyatt G. H., Keller J. L., Jaeschke R., et al. The N-of-1 randomized controlled trial: clinical usefulness. Annals of Internal Medicine. 1990;112(4):293–299. doi: 10.7326/0003-4819-112-4-293.
    1. Lee B. Y., Lee S., Lee J. S., et al. Validity and reliability of CAT and dyspnea-12 in bronchiectasis and tuberculous destroyed lung. Tuberculosis and Respiratory Diseases. 2012;72(6):p. 467. doi: 10.4046/trd.2012.72.6.467.
    1. Dodd J. W., Hogg L., Nolan J., et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. a multicentre, prospective study. Thorax. 2011;66(5):425–429. doi: 10.1136/thx.2010.156372.
    1. Chen K. W., Chow S. C., Li G. A note on sample size determination for bioequivalence studies with high-order crossover designs. Journal of Pharmacokinetics and Biopharmaceutics. 1997;25(6):753–765. doi: 10.1023/a:1025738019069.
    1. Chow S. C., Shao J., Wang H. Sample Size Calculations in Clinical Research. New York, NY, USA: Marcel Dekker; 2003.
    1. Nikles J., Mitchell G. K., Schluter P., et al. Aggregating single patient (N-of-1) trials in populations where recruitment and retention was difficult: the case of palliative care. Journal of Clinical Epidemiology. 2011;64(5):471–480. doi: 10.1016/j.jclinepi.2010.05.009.
    1. Schluter P. J., Ware R. S. Single patient (N-of-1) trials with binary treatment preference. Statistics in Medicine. 2005;24(17):2625–2636. doi: 10.1002/sim.2132.
    1. Zucker D. R., Schmid C. H., McIntosh M. W., D’Agostino R. B., Selker H. P., Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. Journal of Clinical Epidemiology. 1997;50(4):401–410. doi: 10.1016/s0895-4356(96)00429-5.
    1. Zucker D. R., Ruthazer R., Schmid C. H. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. Journal of Clinical Epidemiology. 2010;63(12):1312–1323. doi: 10.1016/j.jclinepi.2010.04.020.
    1. Nikles J., Mitchell G., McKinlay L., et al. A series of N-of-1 trials of stimulants in brain injured children. NeuroRehabilitation. 2017;40(1):11–21. doi: 10.3233/nre-161386.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi